By The Weekly Vision Reporter
England has begun distributing a new HIV treatment described by officials as “trailblazing,” offering fresh hope to a small but vulnerable group of patients whose infections have become resistant to every existing antiretroviral medicine. The drug, lenacapavir, was recommended by NHS England’s Clinical Priorities Advisory Group (CPAG) and announced in mid-August. It marks the first time the health service has made the medicine routinely available for treatment, following its earlier use as an HIV-prevention injection introduced in October last year.
Unlike conventional antiretroviral therapies, which target the enzymes HIV uses to replicate, lenacapavir attacks the virus’s protective outer shell, known as the capsid, preventing it from reproducing inside the body. Health officials have described the approach as a departure from decades of standard HIV treatment protocol.
Patients begin with a short course of tablets, one on each of the first two days, followed by a third on day eight, before receiving two injections on day fifteen. After that, they move onto a twice-yearly injection, a considerably less demanding regimen than the daily pill schedules most HIV patients rely on.
The treatment is aimed at a narrow category of patients: those whose HIV has mutated into a form resistant to all other available medicines. NHS England says around 92 people are currently eligible and will be contacted within weeks to begin treatment, with that number projected to rise to close to 300 over the next three years.
More than 100,000 people are living with HIV in England. The vast majority manage the virus successfully with standard antiretroviral therapy, which suppresses it to an undetectable level and prevents onward transmission. Lenacapavir is intended specifically for the small minority for whom those options have failed.
John Stewart, NHS England’s national director for specialised commissioning, said the drug offers “a lifeline” to patients who previously had nowhere else to turn. Campaigners have welcomed the decision as a significant step in the country’s wider strategy to end new HIV transmissions by 2030.
While the rollout is specific to the NHS, the development is being watched closely by public health systems and HIV programmes internationally, including in countries such as Kenya that continue to manage substantial HIV treatment and prevention burdens. Long-acting, capsid-targeting drugs like lenacapavir are increasingly seen as a template for how resistant infections might eventually be managed outside high-income health systems. However, cost and distribution remain significant barriers to wider access in lower- and middle-income countries.
For now, the treatment remains confined to a small patient population in England. Still, its approval adds to a growing body of evidence supporting capsid inhibitors as a viable next-generation approach to HIV care, one that global health bodies and donor-funded programmes may look to expand in the coming years.
